Pfizer Total Common and Preferred Stock Dividends Paid 2010-2023 | PFE

Pfizer annual/quarterly total common and preferred stock dividends paid history and growth rate from 2010 to 2023. Total common and preferred stock dividends paid can be defined as the cash outflow for all company dividends paid out to preferred and common shareholders.
  • Pfizer total common and preferred stock dividends paid for the quarter ending December 31, 2023 were $-9.247B, a 2.94% increase year-over-year.
  • Pfizer total common and preferred stock dividends paid for the twelve months ending December 31, 2023 were $-23.100B, a 2.84% increase year-over-year.
  • Pfizer annual total common and preferred stock dividends paid for 2023 were $-9.247B, a 2.94% increase from 2022.
  • Pfizer annual total common and preferred stock dividends paid for 2022 were $-8.983B, a 2.91% increase from 2021.
  • Pfizer annual total common and preferred stock dividends paid for 2021 were $-8.729B, a 3.42% increase from 2020.
Pfizer Annual Total Common and Preferred Stock Dividends Paid
(Millions of US $)
2023 $-9,247
2022 $-8,983
2021 $-8,729
2020 $-8,440
2019 $-8,043
2018 $-7,978
2017 $-7,659
2016 $-7,317
2015 $-6,940
2014 $-6,609
2013 $-6,580
2012 $-6,534
2011 $-6,234
2010 $-6,088
2009 $-5,548
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $149.038B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.528B 117.99
Novo Nordisk (NVO) Denmark $577.276B 47.56
Johnson & Johnson (JNJ) United States $360.407B 14.30
Merck (MRK) United States $321.391B 84.59
AbbVie (ABBV) United States $300.196B 15.26
AstraZeneca (AZN) United Kingdom $219.666B 19.46
Novartis AG (NVS) Switzerland $198.840B 14.10
Sanofi (SNY) $120.637B 10.86
Innoviva (INVA) United States $0.959B 6.77